264 related articles for article (PubMed ID: 22538135)
1. Intrinsic fibrillation of fast-acting insulin analogs.
Woods RJ; Alarcón J; McVey E; Pettis RJ
J Diabetes Sci Technol; 2012 Mar; 6(2):265-76. PubMed ID: 22538135
[TBL] [Abstract][Full Text] [Related]
2. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
Teska BM; Alarcón J; Pettis RJ; Randolph TW; Carpenter JF
J Pharm Sci; 2014 Aug; 103(8):2255-67. PubMed ID: 24909933
[TBL] [Abstract][Full Text] [Related]
3. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
[TBL] [Abstract][Full Text] [Related]
4. Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.
da Silva DC; Lima LMTR
Int J Pharm; 2018 Aug; 547(1-2):621-629. PubMed ID: 29928940
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
Bode BW
Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
[TBL] [Abstract][Full Text] [Related]
6. Profiling Insulin Oligomeric States by
Falk BT; Liang Y; McCoy MA
J Pharm Sci; 2020 Jan; 109(1):922-926. PubMed ID: 31449814
[TBL] [Abstract][Full Text] [Related]
7. Insulin fibrillation and protein design: topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir.
Phillips NB; Whittaker J; Ismail-Beigi F; Weiss MA
J Diabetes Sci Technol; 2012 Mar; 6(2):277-88. PubMed ID: 22538136
[TBL] [Abstract][Full Text] [Related]
8. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
Lindström T; Hedman CA; Arnqvist HJ
Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
[TBL] [Abstract][Full Text] [Related]
9. Concentration and Chemical Stability of Commercially Available Insulins: A High-Resolution Mass Spectrometry Study.
Baechler F; Stettler C; Vogt B; Bally L; Groessl M
Diabetes Technol Ther; 2020 Apr; 22(4):326-329. PubMed ID: 32031881
[TBL] [Abstract][Full Text] [Related]
10. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.
Kerr D; Wizemann E; Senstius J; Zacho M; Ampudia-Blasco FJ
J Diabetes Sci Technol; 2013 Nov; 7(6):1595-606. PubMed ID: 24351186
[TBL] [Abstract][Full Text] [Related]
11. Formulation Excipients and Their Role in Insulin Stability and Association State in Formulation.
Maikawa CL; Nguyen LT; Mann JL; Appel EA
Pharm Res; 2022 Nov; 39(11):2721-2728. PubMed ID: 35978148
[TBL] [Abstract][Full Text] [Related]
12. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump.
Senesh G; Bushi D; Neta A; Yodfat O
J Diabetes Sci Technol; 2010 Jan; 4(1):104-10. PubMed ID: 20167173
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
[TBL] [Abstract][Full Text] [Related]
14. Role of ultrafast-acting insulin analogues in the management of diabetes.
Kruger DF; Novak LM
J Am Assoc Nurse Pract; 2019 Sep; 31(9):537-548. PubMed ID: 31385938
[TBL] [Abstract][Full Text] [Related]
15. Insulin glulisine complementing basal insulins: a review of structure and activity.
Becker RH
Diabetes Technol Ther; 2007 Feb; 9(1):109-21. PubMed ID: 17316105
[TBL] [Abstract][Full Text] [Related]
16. Analysis of oligomeric stability of insulin analogs using hydrogen/deuterium exchange mass spectrometry.
Nakazawa S; Hashii N; Harazono A; Kawasaki N
Anal Biochem; 2012 Jan; 420(1):61-7. PubMed ID: 21951784
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro.
Chao M; Wang W; Zhang Y; Lu X; Meng J; Ning G
Endocrine; 2010 Aug; 38(1):48-52. PubMed ID: 20960101
[TBL] [Abstract][Full Text] [Related]
18. The molecular chaperone alpha-crystallin as an excipient in an insulin formulation.
Rasmussen T; Tantipolphan R; van de Weert M; Jiskoot W
Pharm Res; 2010 Jul; 27(7):1337-47. PubMed ID: 20333453
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.
Fordan S; Raskin P
Vasc Health Risk Manag; 2009; 5(1):225-31. PubMed ID: 19436644
[TBL] [Abstract][Full Text] [Related]
20. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism.
Nielsen L; Khurana R; Coats A; Frokjaer S; Brange J; Vyas S; Uversky VN; Fink AL
Biochemistry; 2001 May; 40(20):6036-46. PubMed ID: 11352739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
